Cargando…

Low-Dose Decitabine Monotherapy Reverses Mixed Chimerism in Adult Patients After Allogeneic Hematopoietic Stem Cell Transplantation With Myeloablative Conditioning Regimen: A Pilot Phase II Study

T cell mixed chimerism (MC) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with myeloablative conditioning for hematological malignancies may indicate engraftment failure or disease relapse. Immune modulation, such as donor lymphocyte infusion (DLI) or the rapid tapering-off or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ling, Wang, Li-ning, Zhou, Ji-fang, Gao, Wen-hui, Jiang, Chuan-he, Tang, Wei, Zhao, Wei-li, Hu, Jiong, Jiang, Jie-ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940531/ https://www.ncbi.nlm.nih.gov/pubmed/33708780 http://dx.doi.org/10.3389/fmed.2021.627946

Ejemplares similares

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein–Barr virus infection
por: Luo, Yanhui, et al.
Publicado: (2022)

Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation
por: Goh, Ri-Young, et al.
Publicado: (2011)

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation
por: Zhu, Jinye, et al.
Publicado: (2023)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study
por: Çiftçiler, Rafiye, et al.
Publicado: (2019)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia
por: Liu, Jia, et al.
Publicado: (2021)

SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS
por: Luger, Selina M., et al.
Publicado: (2011)

Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin
por: Park, Bo-Kyoung, et al.
Publicado: (2018)

A gut microbiota score predicting acute graft‐versus‐host disease following myeloablative allogeneic hematopoietic stem cell transplantation
por: Han, Lijie, et al.
Publicado: (2019)

Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease
por: Limerick, Emily, et al.
Publicado: (2022)

Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease
por: Wang, Qing Ya, et al.
Publicado: (2019)

Comparison of Non-myeloablative Conditioning Regimens for Lymphoproliferative Disorders
por: Hong, Sanghee, et al.
Publicado: (2014)

Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation
por: de Kort, Elizabeth A., et al.
Publicado: (2019)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
por: Alvarez, Maite, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
por: Cooper, Jason P., et al.
Publicado: (2020)

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
por: Rahmat, Leena T., et al.
Publicado: (2018)

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
por: Nakamura, R, et al.
Publicado: (2002)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
por: Wang, Yuxin, et al.
Publicado: (2022)

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
por: Campbell, P, et al.
Publicado: (2014)

Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report
por: Cheung, Verna, et al.
Publicado: (2022)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells
por: Grimaldi, Francesco, et al.
Publicado: (2017)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
por: Kong, Xiaoshuang, et al.
Publicado: (2023)

The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation
por: Uppugunduri, Chakradhara Rao S., et al.
Publicado: (2017)

Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies
por: Levrat, Emmanuel, et al.
Publicado: (2015)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Walter, Roland B., et al.
Publicado: (2014)

Modulation of Allogeneic CD8(+) T-Cell Response by DZNep Controls GVHD While Preserving Hematopoietic Chimerism
por: Wang, Jina, et al.
Publicado: (2013)

Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
por: Yao, Wen, et al.
Publicado: (2022)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

IL-10 modified mRNA monotherapy prolongs survival after composite facial allografting through the induction of mixed chimerism
por: Aviña, Ana Elena, et al.
Publicado: (2023)

Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction
por: van Balen, Peter, et al.
Publicado: (2018)

(GT)(n) Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Køllgaard, Tania, et al.
Publicado: (2016)

Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Analysis in the Rituximab Era
por: Mussetti, Alberto, et al.
Publicado: (2015)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_52c5eqgduj0qchebde0nv7okdj